Association between Pulmonary Aspergillosis and Cytomegalovirus Reactivation in Critically Ill COVID-19 Patients: A Prospective Observational Cohort Study
Authors:
- Valeria CaciagliVCValeria Caciagli
- Irene ColorettiICIrene Coloretti
- Marta TalamontiMTMarta Talamonti
- Carlotta FarinelliCFCarlotta Farinelli
- Ilenia GattoIGIlenia Gatto
- Emanuela BiagioniEBEmanuela Biagioni
- Mario SartiMSMario Sarti
- Erica FranceschiniEFErica Franceschini
- Marianna MeschiariMMMarianna Meschiari
- Cristina MussiniCMCristina Mussini
- Roberto TonelliRTRoberto Tonelli
- Enrico CliniEnrico Clini
Open Access
Abstract
COVID-19-associated invasive pulmonary aspergillosis (CAPA) is common and is associated with poor outcomes in critically ill patients. This prospective observational study aimed to explore the association between CAPA development and the incidence and prognosis of cytomegalovirus (CMV) reactivation in critically ill COVID-19 patients. We included all consecutive critically ill adult patients with confirmed COVID-19 infection who were admitted to three COVID-19 intensive care units (ICUs) in an Italian hospital from 25 February 2020 to 8 May 2022. A standardized procedure was employed for early detection of CAPA. Risk factors associated with CAPA and CMV reactivation and the association between CMV recurrence and mortality were estimated using adjusted Cox proportional hazard regression models. CAPA occurred in 96 patients (16.6%) of the 579 patients analyzed. Among the CAPA population, 40 (41.7%) patients developed CMV blood reactivation with a median time of 18 days (IQR 7–27). The CAPA+CMV group did not exhibit a significantly higher 90-day mortality rate (62.5% vs. 48.2%) than the CAPA alone group (p = 0.166). The CAPA+CMV group had a longer ICU stay, fewer ventilation-free days, and a higher rate of secondary bacterial infections than the control group of CAPA alone. In the CAPA population, prior immunosuppression was the only independent risk factor for CMV reactivation (HR 2.33, 95% C.I. 1.21–4.48, p = 0.011). In critically ill COVID-19 patients, CMV reactivation is common in those with a previous CAPA diagnosis. Basal immunosuppression before COVID-19 appeared to be the primary independent variable affecting CMV reactivation in patients with CAPA. Furthermore, the association of CAPA+CMV versus CAPA alone appears to impact ICU length of stay and secondary bacterial infections but not mortality.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research ConsortiumClinical Infectious Diseases, 2019
- Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort studyThe Lancet Respiratory Medicine, 2018
- International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumoniaEuropean Respiratory Journal, 2017
- Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical IllnessJAMA, 2017
- Association Between Cytomegalovirus Reactivation and Clinical Outcomes in Immunocompetent Critically Ill Patients: A Systematic Review and Meta-AnalysisOpen Forum Infectious Diseases, 2017
- Hidden Killers: Human Fungal InfectionsScience Translational Medicine, 2012
- Acute Respiratory Distress SyndromeJAMA, 2012
- IDSA Guidelines for the Diagnosis and Management of Intravascular Catheter‐Related Bloodstream InfectionClinical Infectious Diseases, 2009
- Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patientsBone Marrow Transplantation, 2009
- Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2006